AORT vs LMAT

Key Takeaways

• Artivion (AORT) is a high-growth cardiac and aortic surgery device company with revenue expanding at a double-digit pace, yet the stock has posted a year-to-date decline exceeding 40% amid broader volatility.
• LeMaitre Vascular (LMAT) has delivered consistent double-digit revenue growth with industry-leading net margins near 24% and a year-to-date gain of roughly 28%.
• LeMaitre offers a growing dividend (yield around 0.87%) with 14 consecutive years of increases; Artivion pays no dividend and reinvests aggressively into its clinical pipeline.
• Artivion carries significantly higher valuation multiples (P/E of approximately 114) and higher beta (1.25) compared to LeMaitre (P/E of roughly 38, beta of 0.52).
• Both companies operate in the medical device space but target distinct surgical sub-specialties, creating different risk-reward profiles for investors.
• Wall Street analysts currently assign a "Strong Buy" consensus to Artivion with a price target implying over 50% upside, while rating LeMaitre a "Moderate Buy."

Introduction

Investors tracking the medical device sector often encounter two specialized names that, while operating in adjacent surgical niches, present markedly different investment profiles. AORT (Artivion, Inc.) focuses on cardiac and aortic surgery, serving a global market with stent grafts, mechanical heart valves, and tissue preservation services. LMAT (LeMaitre Vascular, Inc.) centers on peripheral vascular disease, supplying implants and disposable devices to vascular surgeons worldwide. This comparison examines how these two companies stack up across growth trajectories, profitability, market sentiment, and risk characteristics — offering a side-by-side view relevant to growth-oriented investors, income seekers, and anyone evaluating relative positioning within healthcare.

AORT Overview and Recent Performance

Artivion, formerly known as CryoLife until its 2022 rebranding, develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The company operates across four major product groups: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, with a presence in more than 100 countries.

In recent quarters, Artivion has demonstrated robust commercial momentum. For the full year 2025, the company reported non-GAAP revenue of approximately $443.6 million, representing roughly 13% constant currency growth. Stent graft revenues surged by 36% year-over-year on a constant currency basis in the fourth quarter, while On-X heart valves grew 24%, driven by new clinical data supporting their use in younger patient populations. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $89.6 million for the full year, a 26% increase, with margins expanding meaningfully.

Despite this operational strength, AORT shares have experienced considerable pressure. The stock traded near $27.55 in recent sessions, down roughly 41% year-to-date and substantially below its 52-week high of $48.25. Contributing factors include investor concerns around elevated spending on clinical trials, lingering effects from a prior cybersecurity incident that constrained tissue processing revenue, and broader rotations away from higher-multiple growth names. On the catalyst front, the company filed the final PMA (Premarket Approval) module for its AMDS hybrid prosthesis, with FDA approval anticipated by mid-2026, and the NEXUS endovascular stent graft system represents another potential regulatory milestone later in the year.

LMAT Overview and Recent Performance

LeMaitre Vascular, headquartered in Burlington, Massachusetts, specializes in devices, implants, and services for the treatment of peripheral vascular disease — a condition affecting over 200 million people globally. The company's diversified product portfolio includes grafts, catheters, shunts, valvulotomes, and biologic patches, all marketed primarily to vascular surgeons through a direct sales force.

LeMaitre has delivered steady and profitable growth in recent periods. Full-year 2025 revenue reached approximately $249 million, reflecting 14% organic growth, while net income climbed to roughly $57.7 million. The company's gross margin expanded to 71.7% in the fourth quarter, and operating margin hit 29%, highlighting the benefits of pricing power, manufacturing efficiencies, and disciplined expense management. Grafts and shunts have been standout product categories, while the international launch of Artegraft biologic grafts has exceeded initial expectations, contributing meaningfully to EMEA (Europe, Middle East, and Africa) sales growth of 29% in the most recent quarter.

In the market, LMAT shares have reflected this consistent execution. Trading near $103.57 in recent sessions, the stock has gained roughly 28% year-to-date and approximately 27% over the trailing twelve months. With a beta of just 0.52, LeMaitre has exhibited substantially lower volatility than the broader market. The company also raised its quarterly dividend by 25% to $0.25 per share and authorized a $100 million share repurchase program, signaling confidence in its cash generation. The balance sheet remains strong with $359 million in cash and securities at year-end 2025, providing ample capacity for potential M&A (mergers and acquisitions).

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to navigate shifting market conditions. While Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, only those demonstrating the strongest alignment with current market dynamics earn a place in this featured section. The bots span a wide variety of trading styles — from short-term momentum strategies to longer-duration trend-following approaches — and each comes with its own track record, statistical profile, and set of traded tickers. Some bots showcased on the page have generated annualized returns in the double digits, and the platform provides transparency into metrics such as win rates, drawdown levels, and trade frequency. For traders and investors interested in automating their decision-making with data-driven tools, exploring the Trending AI Robots page can offer a practical starting point.

Head-to-Head Comparison

Although both companies operate in the medical device sector, the contrast between Artivion and LeMaitre Vascular is striking across nearly every financial dimension.

Business Model and Market Focus: Artivion targets cardiac and aortic surgeons with a mix of high-acuity implantable devices (stent grafts, mechanical heart valves) and tissue preservation services. Its growth relies heavily on new product introductions, regulatory approvals, and clinical trial outcomes. LeMaitre, by contrast, serves vascular surgeons with a broad portfolio of established disposable and implantable devices used in peripheral procedures — a more predictable, replacement-driven market.

Growth vs. Profitability: Artivion's revenue growth in the mid-teens percentage range outpaces LeMaitre's low-to-mid-teens growth, but LeMaitre converts far more of that revenue into profit. LeMaitre's net margin of approximately 24% dwarfs Artivion's roughly 2.5%, reflecting LeMaitre's asset-light manufacturing model, pricing power, and absence of large-scale clinical trial expenses.

Risk Profile: With a beta of 1.25, Artivion is roughly 25% more volatile than the S&P 500, while LeMaitre's beta of 0.52 suggests it moves at roughly half the market's amplitude. Artivion also faces binary regulatory risk tied to AMDS and NEXUS approval timelines. LeMaitre's risk factors are more operational — including the integration of potential acquisitions and a cyber incident disclosed in early 2026 that management described as minimally disruptive.

Capital Allocation: LeMaitre returns capital to shareholders through a growing dividend (14 consecutive years of increases) and an active buyback program. Artivion reinvests substantially all free cash flow into its clinical pipeline, R&D (research and development), and manufacturing infrastructure — a profile more suited to investors prioritizing long-term capital appreciation over current income.

Valuation: LeMaitre trades at approximately 38 times trailing earnings and roughly 9 times sales, while Artivion trades at around 114 times earnings and approximately 3 times sales — reflecting the market's willingness to pay a premium for Artivion's pipeline optionality despite its lower current profitability.

Tickeron AI Verdict

Based on observable trend consistency, stability metrics, and relative market positioning, Tickeron's AI-driven analysis would likely favor LMAT in the current environment — but with an important caveat. LeMaitre's combination of consistent earnings growth, expanding margins, positive price momentum, low beta, and shareholder-friendly capital allocation creates a steadier and more statistically reliable trend profile, which many AI models are designed to identify and prioritize. Artivion, while demonstrating strong operational momentum and commanding significant analyst enthusiasm, carries higher volatility, a larger drawdown from its 52-week high, and heavier dependence on binary regulatory catalysts. That said, AI systems employing momentum or contrarian strategies may identify Artivion's sharp year-to-date decline and substantial analyst upside target as an opportunity — making the verdict contingent on the specific algorithm's timeframe and risk parameters. On balance, LeMaitre's trend consistency and lower risk profile give it the probabilistic edge under most systematic frameworks.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations